A carregar...
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
OBJECTIVE: Treatment of dyslipidemia lowers cardiovascular (CV) risk. Although statin use is a cornerstone therapy, many patients are not achieving their risk-specific low-density lipoprotein cholesterol (LDL-C) goals. The proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies h...
Na minha lista:
| Publicado no: | J Drug Assess |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7470150/ https://ncbi.nlm.nih.gov/pubmed/32939318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2020.1801452 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|